New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
06:05 EDTBIDU, OPKStocks with implied volatility movement; BIDU OPK
Stocks with implied volatility movement; Baidu (BIDU) 39, OPKO Health (OPK) 67 according to iVolatility.
News For BIDU;OPK From The Last 14 Days
Check below for free stories on BIDU;OPK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
09:37 EDTBIDUActive equity options trading on open
Subscribe for More Information
09:18 EDTOPKOPKO Health says second Rayaldee Phase 3 trial meets primary endpoints
Subscribe for More Information
September 22, 2014
08:04 EDTBIDUAltera and Baidu collaborate on FPGA-based acceleration for cloud data centers
Subscribe for More Information
September 19, 2014
16:00 EDTBIDUOptions Update; September 19, 2014
Subscribe for More Information
09:37 EDTBIDUActive equity options trading on open
Subscribe for More Information
September 18, 2014
16:00 EDTBIDUOptions Update; September 18, 2014
Subscribe for More Information
07:35 EDTBIDUBaidu volatility low into Alibaba IPO
Baidu September call option implied volatility is at 28, September weekly is at 28, October is at 32, December is at 33; compared to its 26-week average of 38 according to Track Data, suggesting decreasing price movement.
September 17, 2014
12:01 EDTBIDUSeagate signs strategic agreement with Baidu
Subscribe for More Information
September 15, 2014
09:14 EDTOPKOPKO Health launches 4Kscore Test in Europe
Subscribe for More Information
06:40 EDTBIDUNew Apple products blasted by Baidu, WantChinaTimes says
Apple's (AAPL) new iPhones are low quality products with high breakdown rates, and the devices will not generate strong sales in China, Chinese search engine Baidu (BIDU) said in a blog on Saturday, according to WantChinaTimes. Another blog from Baidu stated that Apple is not innovating and is not taking its smart watch seriously enough, WantChinaTimes reported. Reference Link
September 11, 2014
09:03 EDTOPKOPKO announces publication of MOD-4023 Phase 2 dose finding study
OPKO Health announced that the abstract “Top Line Results of Once-Weekly, CTP-Modified Human Growth Hormone: Phase 2 Dose Finding Study in Children with Growth Hormone Deficiency" has been selected for late breaking oral presentation at the 53rd Annual Meeting of the European Society of Paediatric Endocrinology on September 20. OPKO will present six month efficacy, safety, pharmacokinetic and pharmacodynamics data from the company's advanced phase 2 trial for its long acting human growth hormone hGH-CTP, or MOD-4023, in growth hormone deficient pediatric subjects. In addition, OPKO’s posters to be presented during the conference have been recognized for outstanding advancement by ESPE and will introduce additional data, as well as analytical characteristics of hGH-CTP in preparation for the planned pediatric phase 3 study. The data from this study supported once-weekly dosing for hGH-CTP and also enabled the selection of an appropriate dose to demonstrate non-inferiority compared to daily hGH in the upcoming phase 3 study. hGH-CTP demonstrated a good safety and tolerability profile in this ongoing study.
September 10, 2014
08:34 EDTBIDUCtrip.com confirms removal of hotel listings from Qunar, Marbridge Daily says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use